| Edward M. Kaye |
Dr. Edward M. Kaye, MD, is an Independent Director at Avidity Biosciences, Inc., a Chief Executive Officer & Director at Stoke Therapeutics, Inc., an Independent Director at Cytokinetics, Inc. and an Advisory Board Member at CureDuchenne Ventures LLC. He is on the Board of Directors at Avidity Biosciences, Inc., Stoke Therapeutics, Inc., Cytokinetics, Inc. and Massachusetts Biotechnology Council. Dr. Kaye was previously employed as an Independent Director by NeuroVia, Inc., a Group Vice President-Clinical Development by Genzyme Corp., a Chief-Biochemical Genetics by The Children's Hospital of Philadelphia, a Chief-Neurology by St. Christopher's Hospital for Children LLC, and an Associate Professor by Perelman School of Medicine. He also served on the board at Sarepta Therapeutics, Inc. He received his undergraduate degree from Loyola University New Orleans and a doctorate degree from Stritch School of Medicine. |
| Joan Wood |
Ms. Joan Wood is a Chief Human Resources Officer at Stoke Therapeutics, Inc. Ms. Wood was previously employed as a Chief Human Resources Officer & Senior VP by Karyopharm Therapeutics, Inc., a Vice President & Head-Human Resources by Sarepta Therapeutics, Inc., and a Senior Vice President-Human Resources by Genzyme Corp. She also served on the board at National Initiative for Children's Health Care Quality, Inc. and Writeboston. She received her undergraduate degree from the University of Saint Joseph and a graduate degree from Boston University. |
| Thomas Leggett |
Thomas Leggett is an Independent Director at Research Alliance Corp. II, an Independent Non-Executive Director at Clover Biopharmaceuticals Ltd., and the Chief Financial & Accounting Officer at Stoke Therapeutics, Inc. He previously worked as an Executive Director at UBS Securities LLC from 2009 to 2015, Treasurer & Head-Finance Business Development at Purdue Pharma LP in 2016, Chief Financial Officer & Senior VP-Finance at Axcella Health, Inc. from 2017 to 2019, and Chief Financial & Accounting Officer at Black Diamond Therapeutics, Inc. from 2019 to 2021. He also served as the Chief Financial Officer at Affinia Therapeutics, Inc. from 2021 to 2024. Mr. Leggett obtained his undergraduate degree from The Trustees of Columbia University in The City of New York in 1999 and an MBA from The Wharton School of the University of Pennsylvania in 2004. |
| Shamim Ruff |
Ms. Shamim Ruff is a Chief Regulatory Officer at Stoke Therapeutics, Inc., a Member at American Society of Clinical Oncology, Inc., a Member at American Society of Gene & Cell Therapy, a Member at Develop Innovate Advance, a Member at Regulatory Affairs Professionals Society and a Member at The Royal Society of Chemistry. Ms. Ruff was previously employed as an Independent Director by Reata Pharmaceuticals, Inc., a Chief Regulatory Affairs Officer & Senior VP by Sarepta Therapeutics, Inc., a Vice President-Regulatory Affairs by Genzyme Corp., and an Executive Director-US & Global Regulatory Affairs by Amgen, Inc. She received her undergraduate degree from the University of Leicester and a graduate degree from Loughborough University. |
| Jason Hoitt |
Jason Hoitt is currently the Chief Commercial Officer at Stoke Therapeutics, Inc. He previously held positions as the Head-US Sales at Sarepta Therapeutics, Inc. from 2013 to 2017, Vice President & Head-US Sales at Insmed, Inc. in 2017 to 2018, Chief Commercial Officer at Dova Pharmaceuticals, Inc. from 2018 to 2019, and Chief Commercial Officer at Provention Bio, Inc. from 2020 to 2023. Mr. Hoitt obtained his undergraduate degree from the College of the Holy Cross (Massachusetts) in 1999. |
| Barry S. Ticho |
Mr. Barry S. Ticho is a Chief Medical Officer at Stoke Therapeutics, Inc. Mr. Ticho was previously employed as a Head-Cardiovascular & Metabolic Diseases by Moderna Therapeutics Inc, a Head-External Research & Development Innovation by Pfizer Inc., a Vice President-Clinical Development by Biogen Idec, Inc., a Member by The General Hospital Corp., and a Member by Harvard Medical School. He also served on the board at Verve Therapeutics, Inc. He received his undergraduate degree from Haverford College and a doctorate degree from The University of Chicago. |
| Huw M. Nash |
Dr. Huw M. Nash is a Chief Operating & Business Officer at Stoke Therapeutics, Inc. Dr. Nash was previously employed as a Vice President-Corporate Development by Aileron Therapeutics, Inc. and a VP-External Collaborations & Founding Scientist by NeoGenesis Pharmaceuticals, Inc. He received his undergraduate degree from Harvard College and a doctorate degree from Harvard University. |
| Seth L. Harrison |
Dr. Seth L. Harrison is an Independent Non-Executive Director at Akero Therapeutics, Inc., a Chairman at Stoke Therapeutics, Inc., a Founder & Managing Partner at Apple Tree venture Managemnet Llc//vc, a Chairman at Adendra Therapeutics Ltd., a Chairman at Aethon Therapeutics, Inc., a Chairman at Braeburn Pharmaceuticals SPRL, a Chairman at Braeburn, Inc., a Chairman at Limelight Bio, Inc., a Chairman at Marengo Therapeutics, Inc., a Chairman at Nereid Therapeutics, Inc., a Chief Executive Officer at Apple Tree Life Sciences, Inc. and a Treasurer & Director at Syntimmune, Inc. He is on the Board of Directors at Akero Therapeutics, Inc., Aulos Bioscience, Inc., Apertor Pharmaceuticals, Inc., Ascidian Therapeutics, Inc., Gala Therapeutics, Inc., Galavant Therapeutics, Inc., Galaxy Medical, Inc., Galvanize Therapeutics, Inc., Harrison Atelier Foundation, Initial Therapeutics Inc, Intergalactic Therapeutics, Inc., Marlinspike Therapeutics, Inc., Nine Square Therapeutics, Inc., Replicate Bioscience, Inc., Tortoise Foundation and Syntimmune, Inc. Dr. Harrison was previously employed as a Non-Executive Deputy Chairman by Heartware Pty Ltd., a Chairman by Tokai Pharmaceuticals, Inc., a Chairman by Cure Forward Corp., a Deputy Chairman by HeartWare International LLC, a Vice Chairman by New York Studio School of Drawing Painting & Sculpture, a General Partner by Oak Investment Partners, and a Venture Partner by Sevin Rosen Bayless Management Co. He also served on the board at International Partnership for Microbicides, Aileron Therapeutics, Inc., Avalo Therapeutics, Inc., CleanSlate Centers, Inc., Corvidia Therapeutics, Inc., Eledon Pharmaceuticals, Inc., The Rockefeller Foundation and Tusker Medical, Inc. He received his undergraduate degree from Princeton University, an MBA from The Trustees of Columbia University in The City of New York and a doctorate degree from The Trustees of Columbia University in The City of New York. |
| Stephen J. Tulipano |
Stephen J. Tulipano is a member of The American Institute of Certified Public Accountants and the Massachusetts Society of Certified Public Accountants, Inc. He is currently serving as the Chief Financial Officer at Stoke Therapeutics, Inc. Additionally, he has held positions as the Director of Corporate Accounting at Biogen, Inc. from 1998 to 2006, Manager of External Reporting at Digital Equipment Corp., Chief Financial Officer and Treasurer at Aldeyra Therapeutics, Inc. from 2014 to 2018, and Chief Financial Officer and Secretary at Javelin Pharmaceuticals, Inc. from 2009 to 2010. Mr. Tulipano obtained an undergraduate degree from Salem State University and an MBA from Sawyer Business School. |
| Adrian R. Krainer |
Adrian R. Krainer is the founder of Stoke Therapeutics, Inc. (founded in 2014) where he holds the title of Independent Director. He is currently the Deputy Director-Research at Cold Spring Harbor Laboratory, Inc. He is also a Member of the National Academy of Sciences, the American Academy of Arts & Sciences, the National Academy of Medicine (United States), the National Academy of Inventors, and the St Giles Foundation, where he holds the title of Professor. Dr. Krainer has an undergraduate degree from The Trustees of Columbia University in The City of New York and a doctorate degree from Harvard University. |
| Arthur O. Tzianabos |
Dr. Arthur O. Tzianabos is a Venture Partner at 5AM Venture Management LLC, an Independent Director at Stoke Therapeutics, Inc. and a Member-Development Board at University of New Hampshire. He is on the Board of Directors at Alliance for Regenerative Medicine, Stoke Therapeutics, Inc., Oxford Biomedica Solutions LLC and Q32 Bio, Inc. Dr. Tzianabos was previously employed as a Chairman by Akouos, Inc., a Chairman by Homology Medicines, Inc., a President & Chief Scientific Officer by OvaScience, Inc., a Senior VP, Head-Research & Early Development by Shire Plc, an Associate Professor & Member by Harvard Medical School, and a Senior VP, Head-Research & Early Development by Shire Pharmaceuticals, Inc. He also served on the board at BIND Therapeutics, Inc. and ArmaGen, Inc. He received his undergraduate degree from Boston College and a doctorate degree from the University of New Hampshire. |
| Jennifer C. Burstein |
Ms. Jennifer C. Burstein is a Senior Vice President-Finance Operations at Treeline Biosciences, Inc. and an Independent Director at Stoke Therapeutics, Inc. She is on the Board of Directors at Stoke Therapeutics, Inc. Ms. Burstein was previously employed as a Senior Vice President-Finance by Loxo Oncology, Inc., a Vice President-Finance by Acorda Therapeutics, Inc., and a Senior Director-Accounting by Oldtech, Inc. She received her undergraduate degree from State University of New York at Buffalo and an MBA from State University of New York at Buffalo. |
| Julie Anne Smith |
Julie Anne Smith is currently the Chief Executive Officer & Director at Nuvig Therapeutics, Inc., the Independent Director at Exelixis, Inc., and the Independent Director at Stoke Therapeutics, Inc. She previously held positions as the President, Chief Executive Officer & Director at Horizon Pharmaceutical LLC, the President & Chief Executive Officer at Raptor Pharmaceuticals, Inc., the President, Chief Executive Officer & Director at Nuredis, Inc., the President, Chief Executive Officer & Director at ESCAPE Bio, Inc., the Director-Channel Strategy & Design at Bristol Myers Squibb Co., the Director-Health & Emerging Companies Sections at Biotechnology Innovation Organization, the Independent Director at Astellas Gene Therapies, Inc., the Vice President-Commercial at Jazz Pharmaceuticals, Inc., the Vice President-Global Marketing at Genzyme General, the Head-Operations & Business Development at Novazyme Pharmaceuticals, Inc., and the Chief Commercial Officer & Vice President at Enobia Pharma, Inc. She obtained her undergraduate degree from Cornell University. |
| Garry E. Menzel |
Garry E. Menzel is currently the Director at Epilepsy Therapy Project. He also holds current positions as an Independent Non-Executive Director at Adaptimmune Therapeutics Plc, an Independent Director at Stoke Therapeutics, Inc., an Independent Director at Black Diamond Therapeutics, Inc., a Member-National Board at Epilepsy Foundation, the Principal at Royal College of Art, and an Operating Partner at GHO Capital Partners LLP. In his former roles, Dr. Menzel served as the President, Chief Executive Officer & Director at TCR2 Therapeutics, Inc. from 2016 to 2023. He was also a Managing Director at Credit Suisse Group AG from 2004 to 2008 and at The Goldman Sachs Group, Inc. from 1994 to 2004. Additionally, he held positions as the Chief Financial Officer at DaVita, Inc. from 2013 to 2015, the Chief Operating Officer at Regulus Therapeutics, Inc. from 2008 to 2013, and the Chief Strategy Officer at Axcella Health, Inc. from 2015 to 2016. He has also worked as a Research Assistant at Smithkline Beecham Plc and as a Consultant at Bain & Co., Inc.Dr. Menzel's education includes an undergraduate degree from Imperial College London in 1985, a doctorate from the University of Cambridge, and an MBA from Stanford Graduate School of Business in 1994. |
| Ian Frederick Smith |
Ian Frederick Smith is currently the Executive Chairman at Solid Biosciences, Inc. He is also a Director at Vertex Pharmaceuticals (Canada), Inc., a Director at Vertex Pharmaceuticals (U.K.) Ltd., an Independent Director at Stoke Therapeutics, Inc., a Director at Alkeus Pharmaceuticals, Inc., a Director at iVexSol, Inc., and a Member of the Institute of Chartered Accountants in England & Wales, The American Institute of Certified Public Accountants, and The Financial Executives Institute. Additionally, he serves as a Senior Advisor at Bain Capital Life Sciences LP and as an Advisor and Director at Foghorn Therapeutics, Inc. Mr. Smith previously held positions as the Executive Chairman at ViaCyte, Inc., a Director at EPIX Pharmaceuticals, Inc., a Director at Tolerx, Inc., an Independent Director at Acorda Therapeutics, Inc., a Director at Predix Pharmaceuticals, Inc., an Independent Director at Infinity Pharmaceuticals, Inc., a Director at Vertex Pharmaceuticals (Europe) Ltd., an Independent Director at IVERIC bio, Inc., and a Co-Managing Director at Vertex Pharmaceuticals (Germany) GmbH. He was also a Partner-Life Science & Technology Practice Group at Ernst & Young LLP and the EVP, Chief Operating & Financial Officer at Vertex Pharmaceuticals, Inc. Mr. Smith obtained his undergraduate degree from Manchester Metropolitan University. |
| Arthur A. Levin |
Dr. Arthur A. Levin is an Independent Director at Stoke Therapeutics, Inc. and a Director & Strategic Leader at Avidity Biosciences, Inc. He is on the Board of Directors at Stoke Therapeutics, Inc., Avidity Biosciences, Inc. and Amylon Therapeutics BV. Dr. Levin was previously employed as an Executive Vice President-Research & Development by 358th Shelf Corp., a Senior Vice President-Development by Ionis Pharmaceuticals, Inc., a Research Leader by Hoffmann-La Roche, Inc., and a Chief Development Officer & Vice President by Roche Innovation Center Copenhagen A/S. He also served on the board at Oligonucleotide Therapeutics Society, Inc. He received his undergraduate degree from Muhlenberg College and a doctorate degree from Rochester Christian University. |
